Thank you, Mr. Chair.
My questions are for Mr. Clark.
Mr. Clark, I actually looked at all of your slides this morning; I read them over back and forth. I noticed that none of the slides talk about an analysis with regard to rare disease patients and patient access. Is there any reason for that?